Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167. The agreement also includes an option to an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s Claudin-18.2 antibody-drug conjugate (ADC) SHR-A1904. In addition, Merck has the option to co-promote both assets in China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231027000141/en/
Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business of Merck (Photo: Business Wire)
“This partnership with Hengrui fully aligns with both our external innovation ambition and our oncology research and development strategy by diversifying our robust internal pipeline in our focus areas of DNA damage response inhibition and antibody-drug conjugates,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business of Merck. “The synergies of these assets with our portfolio offer broad potential for development and the opportunity to advance more therapeutic options for patients with difficult-to-treat cancers. We look forward to leveraging the significant expertise of Hengrui and our strong collaboration ahead.”
Compared with first-generation PARP inhibitors, the selectivity and differentiated safety profile of PARP1-specific inhibitors could offer the opportunity to expand their therapeutic impact in established and new indications. HRS-1167 has shown encouraging signs of clinical activity and patient benefit in Phase I trials as a monotherapy and has higher potential to combine with chemotherapy as well as novel agents, compared with previous attempts with first-generation PARP inhibitors. This aligns with the company’s overarching development approach of DNA damage response (DDR) inhibitors, exploring their synergistic activity and maximizing their potential impact in combination with other anticancer therapies and approaches. Merck is researching the potential to treat cancer through inhibition of multiple targets in the DDR cascade, including ATR, ATM, DNA-PK, and PARP.
Additionally, should the company exercise its option, SHR-A1904 would complement Merck’s internal preclinical and clinical ADC portfolio applying different linker payload technologies. The first ADC developed using Merck’s own technology, M9140, a CEACAM5-targeting ADC, is being evaluated in an ongoing Phase Ia/b study in patients with metastatic colorectal cancer.
"Given the high unmet need in oncology, we are excited to work closely with Merck to bring Hengrui's innovations to cancer patients worldwide,” said Frank Jiang, board member and Chief Strategy Officer of Hengrui Pharma. “Partnering with Merck on our PARP franchise is an important milestone on Hengrui's globalization journey. We look forward to advancing our molecules rapidly through development and reaching patients in need.”
Under the terms of the agreement, Merck will provide Hengrui with an upfront payment of €160 million. Hengrui will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck. Potential payments may total up to €1.4 billion.
Advancing the Future of Cancer Care
At Merck, we strive every day to improve the futures of people living with cancer. Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core. We are determined to maximize the impact of our standard-of-care treatments and to continue pioneering novel medicines. Our vision is to create a world where more cancer patients will become cancer survivors. Learn more at www.merckgrouponcology.com.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Phone: +49 151 1454 7809
Phone: +49 6151 72-3321
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BlueConic Named the Only Challenger in Inaugural 2024 Gartner® Magic Quadrant™ for Customer Data Platforms21.2.2024 18:33:00 CET | Press release
Market-leading customer data platform (CDP) BlueConic today announced that it has been recognized as the only Challenger in the inaugural Magic Quadrant for Customer Data Platforms. We believe this industry recognition marks a major milestone for CDPs and the maturity of the space on a global scale. BlueConic differentiates from other vendors for its: Privacy-by-design philosophy: Maintaining responsible data practices is essential for garnering consumer trust, but maintaining compliance with a patchwork of regulations is only getting more difficult. That’s why BlueConic has been built with privacy at the forefront. The platform has been purposely designed to collect first-party data in ways that ensures it is unified, actionable, and privacy-compliant. Collecting and using data within the framework of privacy regulations like GDPR and CCPA enables companies to build trust and deliver valuable customer experiences, while mitigating their consumer data risk at the same time. Easy-to-use
Bynder named a “Leader” in Digital Asset Management by independent research firm21.2.2024 17:58:00 CET | Press release
Bynder, the global, enterprise digital asset management (DAM) platform, has been named a “Leader” in The Forrester Wave™: Digital Asset Management Systems, Q1 2024 report by Forrester Research, Inc. Bynder received a top score in the revenue category, with the report stating that “Bynder invests to play a transformative role in the digital-first economy.” In the past two years since the last report was launched, Bynder has surpassed $130m in ARR, announced a majority investment from Thomas H. Lee Partners, made two acquisitions, developed its enterprise partner ecosystem, launched more than 45 out of the box integrations and expanded its suite of product offerings to include AI capabilities and other new innovations that are redefining DAM. According to a quote from a customer reference in the report “the AI search and smart filter system in Bynder simplifies the process of finding the exact assets you’re looking for.” These recent AI innovations have highlighted the company’s market l
Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance21.2.2024 17:00:00 CET | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ Whole Transcriptome products. Available to ship in mid-March, Evercode Whole Transcriptome version 3 kits offer researchers a more streamlined workflow, more flexible and higher throughput fixation, and optimized reagents for improved sensitivity in gene detection. With the new version, customers will enjoy a more streamlined and flexible workflow, helping them move from samples to results more quickly. These enhancements are delivered while significantly improving upon the previous version’s sensitivity and library complexity, giving researchers higher biological resolution and insight into their samples. Parse customers already rely on the utility of Evercode fixation, which enables them to fix cells or nuclei when they become available, store them for up to six months, and then sequence them when ready. Fixation i
Tigo Energy Expands Comprehensive Residential Energy Solution for Italy with GO EV Charger21.2.2024 15:00:00 CET | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the launch of the GO EV Charger for the Italian market. A smart residential electric vehicle (EV) charging station, GO EV Charger offers solar installers a way to add e-mobility that seamlessly integrates with the Tigo EI (Energy Intelligence) Residential Solar Solution, which includes inverter, battery system, TS4 MLPE devices, and everything else required for fast, flexible, and dependable solar installations. The Tigo EI Residential Solar Solution will be on display from February 28th to March 1st at KEY - The Energy Transition Expo in Rimini, Italy. Previously released for the German market, the GO EV Charger features seamless integration with the Tigo EI Residential solar-plus-storage solution. The GO EV Charger is available in single- or three-phase variants, up to 22 kW, and delivers high flexibility with multiple charging modes, current limits, and scheduling
Talkdesk Hires Software Veteran Albert Caravelli to Lead, Grow Strategic Alliances and Partners21.2.2024 15:00:00 CET | Press release
Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, today announced that Albert (Al) Caravelli, an accomplished executive experienced in transforming sales and alliances organizations at some of the world’s leading software companies, has joined the company as senior vice president of Alliances and Partners. In this role, Caravelli is responsible for expanding and nurturing Talkdesk’s growing ecosystem of strategic technology alliance partners, global system integrators, and global service providers. Caravelli comes to Talkdesk following nearly nine years at cloud security company Zscaler, where he most recently served as global vice president of strategic alliances and advisory firms, responsible for leading Zscaler’s go-to-market strategy and execution. During this time, he was instrumental in the formation of strategic alliances with multiple companies, including Accenture, Capgemini, Deloitte, HCL, Infosys, AT&T, BT, Cognizant, Deutsche Telekom,